Regular use tied to a 65 percent reduced risk for cardiovascular death<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Dec. 10, 2020 (HealthDay News) — Regular intake of glucosamine\/chondroitin is associated with lower all-cause and cardiovascular disease (CVD) mortality among U.S. adults, according to a study published in the November\/December issue of the Journal of the American Board of Family Medicine.<\/em><\/p>\n Dana E. King, M.D., and Jun Xiang, from West Virginia University in Morgantown, used data from the U.S. National Health and Nutrition Examination Survey (1999 to 2010; 16,686 participants), merged with the 2015 Public-use Linked Mortality File, to investigate the association between regular consumption of glucosamine\/chondroitin and overall and CVD mortality in U.S. adults.<\/p>\n The researchers found that 3.94 percent of participants reported taking glucosamine\/chondroitin for a year or longer. During a median 107 months of follow-up, there were 3,366 total deaths, of which 20.02 percent were due to CVD. Risk for CVD mortality was lower among respondents taking glucosamine\/chondroitin (hazard ratio [HR], 0.51). Glucosamine\/chondroitin use was associated with a risk reduction in all-cause mortality (HR, 0.61) and CVD mortality (HR, 0.35) when controlling for age. The association remained significant when adjusting for age, sex, race, education, smoking status, and physical activity (all-cause mortality: HR, 0.73; CVD mortality: HR, 0.42).<\/p>\n “In my view, it’s important that people know about this, so they can discuss the findings with their doctor and make an informed choice,” King said in a statement. “Glucosamine is over the counter, so it is readily available.”<\/p>\n